Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapies, ...

EGFR BATs is under clinical development by Transtarget and currently in Phase I for Gliosarcoma. According to GlobalData, Phase I drugs for Gliosarcoma does not have sufficient historical data to ...

Alentis Therapeutics ("Alentis"), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+ ...

A panelist discusses how infusion-related reactions to monoclonal antibodies in EGFR-mutated NSCLC can be effectively managed ...

EGFR BATs is under clinical development by Transtarget and currently in Phase I for Glioblastoma Multiforme (GBM).

Californian oncology-focused biotech Avenzo Therapeutics and China-based Duality Biotherapeutics (DualityBio) have entered ...

First-line Rybrevant plus Lazcluze improved survival versus the current standard of care in patients with mutated advanced or ...

Patients with advanced lung tumors harboring EGFR exon 19 deletions or exon 21 L858R mutations are eligible for the combo treatment.

Johnson & Johnson's recently approved combination of Rybrevant and Lazcluze has improved overall survival compared to ...

In this edition of InnovationRx, medical debts will be erased from credit histories, this farm is doubling down on raw milk ...

*仅供医学专业人士阅读参考整理 | 苏旭晗2024年12月底，美国国家综合癌症网络（NCCN）发布了2025.V1版非小细胞肺癌（NSCLC）临床诊疗指南（以下简称指南）。此次指南的发布对NSCLC的临床分期、早期及晚期评估和治疗路径等方面进行了较多 ...